Primary targets of fluoroquinolones in Streptococcus pneumoniae
1Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan. fvbb0984@mb.infoweb.ne.jp
Abstract:
Mutants of wild-type Streptococcus pneumoniae IID553 with mutations in parC were obtained by selection with trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin. All of the parC mutants were cross-resistant to the selecting agents but were not resistant to gatifloxacin and sparfloxacin. On the other hand, gyrA mutants were isolated by selection with gatifloxacin and sparfloxacin. The gyrA mutants were cross-resistant to gatifloxacin and sparfloxacin but were not resistant to the other fluoroquinolones tested. These results suggest that in wild-type S. pneumoniae the primary target of trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin is topoisomerase IV, whereas the primary target of gatifloxacin and sparfloxacin is DNA gyrase.
Insights
Mutations in Streptococcus pneumoniae parC confer resistance to certain fluoroquinolones, indicating topoisomerase IV is their primary target. Conversely, gyrA mutations suggest DNA gyrase is the main target for other fluoroquinolones.
Area of Science:
- Microbiology
- Molecular Biology
- Pharmacology
Background:
- Fluoroquinolones are broad-spectrum antibiotics crucial for treating bacterial infections.
- Understanding the specific molecular targets of fluoroquinolones in bacteria like Streptococcus pneumoniae is essential for guiding antibiotic development and combating resistance.
- Streptococcus pneumoniae is a significant human pathogen, and identifying its susceptibility patterns to different antibiotics is clinically relevant.
Purpose of the Study:
- To elucidate the primary molecular targets of various fluoroquinolones in wild-type Streptococcus pneumoniae.
- To investigate the mechanisms of fluoroquinolone resistance by analyzing mutations in key bacterial enzymes.
Main Methods:
- Inducing and isolating fluoroquinolone-resistant mutants of Streptococcus pneumoniae IID553.
- Utilizing specific fluoroquinolones (trovafloxacin, levofloxacin, norfloxacin, ciprofloxacin, gatifloxacin, sparfloxacin) for selection.
- Analyzing mutations in the parC and gyrA genes, which encode subunits of topoisomerase IV and DNA gyrase, respectively.
- Performing cross-resistance assays to determine the spectrum of resistance.
Main Results:
- Mutants with parC mutations exhibited cross-resistance to trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin, but remained susceptible to gatifloxacin and sparfloxacin.
- Mutants with gyrA mutations were resistant to gatifloxacin and sparfloxacin, but not to the other tested fluoroquinolones.
- These findings differentiate the primary targets based on the observed resistance patterns.
Conclusions:
- In Streptococcus pneumoniae, trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin primarily target topoisomerase IV.
- Gatifloxacin and sparfloxacin primarily target DNA gyrase in Streptococcus pneumoniae.
- This differential targeting has implications for understanding and overcoming fluoroquinolone resistance mechanisms.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
07:44Time-Lapse Epifluorescence Microscopy Imaging of Pseudomonas aeruginosa and Staphylococcus aureus Heterogeneous Phenotypes
Published on: February 14, 2025
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Bacterial DNA Synthesis
Clinical Significance of Antibiotic Resistance
